Yarbrough Capital’s BioNTech BNTX Stock Holding History

Yarbrough Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100	Closed	-$15K	–	201
2022 Q4	$15K	Buy	+100	New	+$15.4K	﹤0.01%	206

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Yarbrough Capital's BNTX Position: Q1 2023 in Review

Yarbrough Capital sold out of BioNTech (BNTX) in Q1 2023, closing a stake of 100 shares — an estimated $15K sold.

Yarbrough Capital first reported a position in BNTX in Q4 2022 and held it in 1 quarter. The position peaked at $15K in Q4 2022. 282 funds tracked by Wall St. Rank hold BNTX as of Q1 2023.

Yarbrough Capital reported no remaining BioNTech position as of Q1 2023 after selling out during the quarter.
Yarbrough Capital sold 100 BioNTech shares in Q1 2023, an estimated $15K.
Yarbrough Capital first reported a position in BioNTech in Q4 2022 and held it in 1 quarter.
Yarbrough Capital's BioNTech position peaked at $15K in Q4 2022.
282 funds tracked by Wall St. Rank held BioNTech as of Q1 2023.

Based on Yarbrough Capital's 13F filing for Q1 2023, filed 13 Apr 2023.